Kornimate/medical-research-clean huggingface dataset:
retinal therapy guided by 3d oct image analysis

Conditions: Age-Related Macular Degeneration; Choroidal Neovascularization

Summary: the main purpose is to find a better way to predict the timing of treatments given to patients with wet age-related macular degeneration using image analysis.

the study focuses on making better use of advanced three-dimensional imaging and analysis to allow physicians to know when a treatment is being effective and thus not overuse it. the study will examine how 3-d optical coherence tomography and related image analysis can be used to assess changes in the macula and retina of patients' eyes. these changes can reveal how well a person is responding to anti-vegf treatment and thus help doctors provide proper treatment timing and care.

Eligibility criteria:
inclusion criteria: * fundoscopically confirmed amd and patient eligible for treatment with anti-vegf exclusion criteria: * patients with a cnv due to other causes (ohs, trauma) * eyes that have been previously treated for cnv

Keywords: retina amd oct
psychotropic medication and psychotherapeutic treatment of adults with intellectual disabilities

Conditions: Intellectual Disability

Summary: mental health service provision of adults with intellectual disabilities (id) is often criticized. there is a lack of empirically studies targeting the psychotropic and psychotherapeutic treatment in this population. the prompt-id study therefore aims to assess the prevalence of psychotropic medication and psychotherapeutic treatment in adults with mild to profound id and the quality of psychotropic medication. it further aims to identify predictors of psychotropic medication, of barriers into psychotherapeutic treatment and of good clinical psychotropic medication prescription practice. it is a cross-sectional, epidemiological study carried out in saxony, germany. approval of the responsible ethics committee was obtained. the inclusion criteria are mild to profound forms of id and an age of 18 years or older. a representative sample is realized by a two-stage sampling procedure. sheltered working and accommodation service providers are stratified by type of service provider and workshop size/type of accommodation. the stratified cluster sampling is realized by a random selection of service providing institutions followed by a random selection of adults with id. an estimated total number of n = 200 study participants via sheltered workshops and n = 400 via residential accommodations need to be contacted to obtain data of approximately n = 131 study participants recruited through sheltered workshops and n = 232 participants through sheltered living institutions. based on a psychotropic medication prevalence of 30%, in- depth interviews about psychotropic prescription practice of an estimated number of n = 109 adults with id are carried out. data collection is realized in interviews with key carers in the living environment and, if applicable, with the prescribing physician. if the adults with id are currently medicated with psychotropics, basic information e.g. about kind, agent, dosage and treatment duration are obtained and a newly developed interview targeting the quality of the psychotropic medication treatment is conducted with the carers. in addition to the prevalence and quality of psychotropic and psychotherapeutic health care utilisation, other parameters like psychiatric symptomatology, problem behavior, sociodemografic and institutional factors and parameters of the provision area are assessed using well- established instruments. findings will fill the lack of representative data that is urgently needed in this often criticized health service area.


Eligibility criteria:
inclusion criteria: * mild to profound levels of id * age of 18 years or older exclusion criteria: -

Keywords: intellectual disability psychotropic medication mental health services evaluation
cardiac magnetic resonance features and outcomes of patients with non-compaction cardiomyopathy - a retrospective follow-up from pakistan

Conditions: Left Ventricle Non-compaction Cardiomyopathy

Summary: objective: to evaluate clinical characteristics, cardiac magnetic resonance imaging features, and outcomes of patients with left ventricle non-compaction.

left ventricle non-compaction cardiomyopathy (lvncc) is a type of myocardial disease characterized by prominent myocardial trabeculae and recesses resulting in two distinct layers of myocardium: compacted layer and the non-compacted layer. it arises due to the failure of left ventricle (lv) maturation and compaction during intra-uterine life (1). as per the position statement from the european society of cardiology, lvncc has been labelled as 'unclassified' type of cardiomyopathy. clinical course can be complicated by heart failure, thromboembolism, or arrhythmia. phenotypic presentation of lvnc can range from extremely thickened layer of non-compacted myocardium to mere presence of prominent trabeculae and recesses albeit a compacted myocardium. transthoracic echocardiography is the first tool to diagnose lvnc. however, cardiac magnetic resonance (cmr) imaging has emerged as a strong tool to differentiate between lvncc from mere hyper-trabeculated lv myocardium when echocardiogram is inconclusive (figure 1 and video 1). various criteria have evolved to diagnose lvnc by cmr. peterson et al defined the end-diastole non-compacted to compacted myocardium ratio of \>2.3 to have good sensitivity, specificity, and negative predictive value for differentiating pathological non-compaction from hyper-trabeculation. with an increase in the use of diagnostic cardiovascular imaging modalities in south-asian (sa) belt, lvnc is being increasingly diagnosed. the exact prevalence of lvnc in sa is not known and phenotypic cmr characteristics, clinical features, and outcomes of lvnc remain unknown for sa population. this brought us to the need of analysing cmr data of lvnc at our centre.

Eligibility criteria:
inclusion criteria: * patients \> 18 years, referred for cmr for further evaluation of cardiomyopathy. exclusion criteria: * patients with intracardiac masses, pericardial diseases and congenital heart diseases were excluded from the study.
evaluating microvascular dysfunction in symptomatic patients with hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: patients with hypertrophic cardiomyopathy are being compared to a control group. imr will be assessed with a pressure wire. clinical f/u at 3 months and 6 months and a 48 hour holter monitor.


Eligibility criteria:
inclusion criteria: * age 18-80 * already have an indication for coronary angiography * previous diagnosis of hypertrophic cardiomyopathy (unless control) exclusion criteria: * fractional flow reserve found to be significant (ffr \< 0.8) * already have a condition associated with or likely to be associated with an elevated imr (diabetes, cardiac syndrome x, takotsubo cardiomyopathy, hypertensive cardiomyopathy, severe aortic stenosis, stemi)

Keywords: index of microvascular resistance microvascular dysfunction
the 1000 first day of life : effect of multi micronutrients supplementation on pregnancy outcomes

Conditions: Maternal Care Patterns; Nutrition, Healthy; Nutritional Deficiency; Maternal-Fetal Relations; Perinatal Outcome; Maternal Outcome

Summary: to monitor the effects of multi micronutrients supplementations during pregnancy towards pregnancy outcomes

a randomized control trial of two clusters : 1st cluster without giving multi micronutrients; 2nd cluster giving multi micronutrients. differences between cluster : additional multi micronutrients by giving : complete multi micronutrients, calcium, vitamin d and dha. the additional multi micronutrients were given since 1st until 3rd trimester for interventions group. there are also additional laboratory examinations for intervention group : vitamin d, lipid profile and zinc level. in control group : we use standard public health care micronutrients (iron supplementation and calcium); and standard blood examinations. ultrasound examination was performed for both cluster since 1st until 3rd trimester.

Eligibility criteria:
inclusion criteria: * first trimester pregnancy * gestational age \< 10 weeks gestation * agree as research participant * living in dki jakarta exclusion criteria: * assisted reproductive * history of pcos * history of chronic hypertension * history of diabetes mellitus * history of preeclampsia * maternal chronic disease : cardiovascular disease; autoimmune condition; malignancy) * plan to move from jakarta prior or during pregnancy * history of recurrent pregnancy loss
comparison of subconjunctival 5-fluorouracil (fu) injection and mitomycin c for treatment of early bleb failure

Conditions: Bleb

Summary: purpose : to evaluate and compare the effectiveness and complication of 5-fu injections and mmc drop in management of early bleb failure . design:randomized clinical trial methods:patients with low injected bleb in first month after filtering or combined surgery with mmc which don't respond to high frequent topical steroids and removal of releasable sutures will be randomize to either 5-fu injection or mitomycin drop 0.02%.for each patient slit photograph in first day of recruiting,first two weeks and first and third month will be obtained.patients will follow for at least 3 months and iop ,bleb configuration will check as primary outcome measures.preoperative and postoperative data,complications,and the need for further surgical procedures will be evaluated.


Eligibility criteria:
inclusion criteria: * patients with low,injected bleb in first month after trabeculectomy or combined trabeculectomy\&phaco which not respond to high frequent topical steroids or removal of releasable sutures exclusion criteria: * injected bleb due to complications of surgery such as button hole formation * injected bleb due to blebitis * bleb leakage * flat ac * pregnant or nursing mothers * injected bleb after bleb reconstruction

Keywords: injected bleb mitomycin drop 5-fu injection early bleb failure
robot-assisted training after acquired brain injury and disorders of consciousness

Conditions: Acquired Brain Injury; Disorders of Consciousness

Summary: the goal of this randomised cross-over feasibility trial is to investigate two intensive robot-assisted training therapies in the early rehabilitation phase after acquired brain injury and disorders of consciousness. the main questions it aims to answer are: * is the protocol feasible concerning inclusion in the study? * is the protocol feasible concerning protocol completion? participants will randomly be assigned to either five days of robot-assisted gait training (gait), two days of pause, then five days of robot-assisted step training (step) or vice versa. the investigators will explore and compare safety events, physiological measures and physical activity levels, behavioural measures, and functional disability outcomes. further, the investigators report intervention and technical parameters in detail.

this is a randomised cross-over feasibility trial, carried out according to the helsinki declaration and approved by the scientific ethics committee of the capital region, denmark. participants are temporarily unable to consent why this obtained from the next of kin. participants start the intervention when 10 minutes of standing in a tilt-table does not cause orthostatic hypotension. participants then recieve five days of intervention, two days pause and then cross over to the other intervention. groups: 1. gait --\> step 2. step --\> gait

Eligibility criteria:
inclusion criteria * admitted for rehabilitation at the department of brain and spinal cord injury, division of brain injury, bodil eskesen centre, rigshospitalet * patients 18 years or older * in the unresponsive wakefulness or minimally conscious state after a moderate to severe acquired brain injury (icd 10: s06, intracranial injury; i60-i69, cerebrovascular diseases) * obtained consent from nearest relative and study guardian. exclusion criteria * weight \> 135 kg (maximum weight for the erigo® tilt table) * height \> 200 cm (maximum height for the lokomat®) * in the confusional state or emerged to full consciousness * if weight bearing is restricted due to, e.g., fractures of the spine, pelvis, or lower limbs. * known osteoporosis of a severity where use of robotic orthoses, according to a physician, is considered a contraindication * if lower limb joints are fixated to a degree that cannot be compensated in the orthoses * no valid consent from the nearest relative or study guardian

Keywords: brain injury traumatic brain injury consciousness robot-assisted gait training tilt-table feasibility cross-over study
vascularity impact on the treatment outcome in malignant pleural mesothelioma(vitmpm)

Conditions: Malignant Pleural Mesotheliomas

Summary: the purpose of this study is to to assess the correlation between the predictive factor of vascularity (cd74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

this is a randomized controlled retrospective study through examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . the cd74 (ln2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using immunohistochemistry test methods.

Eligibility criteria:
inclusion criteria: * histopathological confirmation of malignant pleural mesothelioma . * full clinical data. * availability for follow up: personal communication will be attempted in order to collect missing information. 3-the files of all patients will be reviewed to analyze the following : * operative data if done . * pathological review and immunohistochemistry. * laboratory investigations: (routine investigations: complete blood picture,liver and renal function test) * radiological investigations:( cxr and ct-chest, abdominal and pelvic u\\s and mri ). * treatment protocols applied: radiotherapy and chemotherapy. * response and survival after treatment . exclusion criteria: * cases not receive chemotherapy ,on available of evaluation after treatment
defibrotide for the treatment of severe covid-19

Conditions: Covid19

Summary: the goal of this study is to evaluate the safety and feasibility of defibrotide in covid-19 pneumonia.

this study is a prospective, single-arm, two-cohort, phase 2 pilot study that will evaluate the safety and efficacy of defibrotide in clinically severe covid-19. the defibrotide dose that is approved by the fda for the treatment of post-hsct vod/sos (6.25 mg/kg iv q6 hours) will be used. cohort 1 will consist of patients with covid-19 pneumonia confirmed by pcr and radiography, who are hospitalized with an oxygen requirement (either supplemental o2 or mechanical ventilation), are not on therapeutic dose anticoagulation, and require no more than one vasopressive agent to maintain hemodynamic stability. cohort 2 will consist of patients with covid-19 pneumonia confirmed by pcr and radiography, who are hospitalized in the icu and are at elevated risk of hemorrhage and/or hypotension, the former defined as a requirement for therapeutic dose anticoagulation for active thrombosis, ecmo, or crrt, and the latter defined as a requirement for two vasopressive agents to maintain hemodynamic stability. in cohort 2 only, a 6+6 dose de-escalation design will be utilized, in which if 2 of 6 dlts are experienced in the first 6 subjects, the dose will be reduced from 6.25 mg/kg iv q6hrs to 10mg/kg/d civi. if there are 0 or 1 dlts in the first 6 subjects at the fda-approved dose, another 6 subjects will be enrolled at the same dose. grade 3/4 hemorrhage and significant new hypotension will be considered dlt's.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. active covid-19 infection confirmed by positive sars-cov-2 pcr. 3. radiographic evidence of bilateral pulmonary infiltrates. 4. a life expectancy of at least 24 hours. 5. score of 4-7 on the who ordinal scale. 6. prophylactic dose anticoagulation is allowed for enrollment into cohort 1. therapeutic dose anticoagulation for active thrombosis, ecmo, and/or continuous renal replacement therapy (crrt) is allowed for enrollment into cohort 2 if there is no evidence of bleeding after at least 24 hours of anticoagulation. 7. patient or surrogate able to provide informed consent exclusion criteria: 1. clinically significant acute bleeding. 2. concomitant use of thrombolytic therapy (e.g. t-pa). 3. hemodynamic instability, defined as a requirement for \>1 vasopressor agent for enrollment into cohort 1, and a requirement for \>2 vasopressor agents for enrollment into cohort 2 4. known allergy or hypersensitivity to df. 5. pregnant or lactating.
kidney damage in patients with severe fall in egfr

Conditions: Coronary Artery Stenosis

Summary: this is a pilot study using a randomized, double blinded, comparison of two iodinated contrast agents used during percutaneous coronary intervention (pci). all patients enrolled must have and estimated glomerular filtration \[egfr\] \< 30 ml/min/1.73 m2. statistical summaries will be presented to analyse the various laboratory tests for the two groups.


Eligibility criteria:
inclusion criteria: * provides written informed consent * is at least 18 years of age; * is scheduled for or likely to undergo percutaneous coronary intervention; * has documented estimated glomerular filtration rate \[egfr\] \< 30 ml/min/1.73 m2 calculated with the mdrd formula within 72 hours prior the enrolment. exclusion criteria: * is a pregnant or lactating female * has a history of severe congestive heart failure * has a history of hyperthyroidism * has unstable renal function * has a history of hypersensitivity to iodinated contrast agents
artificial intelligence analysis for magnetic resonance imaging in screening breast cancer in high-risk women

Conditions: Breast Cancer; Magnetic Resonance Imaging

Summary: use convolutional neural networks analysis for classification of contrast-enhancing lesions at multiparametric breast mri. build an abbreviated protocal, and investigate whether an abbreviated protocol was suitable for breast magnetic resonance imaging screening for breast cancer in high-risk chinese women, which can shorten the examination time and avoid enhanced imaging while ensuring the accuracy of the diagnosis.


Eligibility criteria:
inclusion criteria: * patients undergoing full sequence bmri examination * written informed consent and complete the clinical data questionnaire * through the follow-up database, at least 6 months of follow-up results can be obtained to determine whether the diagnosis result is negative/benign/malignant; for patients who need pathological biopsy, the pathological biopsy results shall prevail to determine the lesion benign/malignant. exclusion criteria: * the breast had received radiotherapy, chemotherapy, biology and other treatments before bmri. * signs or symptoms of breast disease * there are contraindications for breast-enhanced mri examinations such as allergy to contrast agents. * patients during lactation or pregnancy

Keywords: breast cancer screening high risk women magnetic resonance imaging deep learning
safety and efficacy of endocuff-assisted colonoscopy for adenoma detection.

Conditions: Adenomatous Polyps

Summary: this study investigated the impact of endocuff-assisted colonoscopy on the adenoma detection rate at colonoscopy. this study involved patients undergoing elective screening or surveillance colonoscopy. patients were randomized to undergo endocuff or regular, high-definition colonoscopy before undergoing a second colonoscopy by the alternate method. the primary outcome measure was the detection rate for adenomas between patients who underwent endocuff first and patients who underwent regular colonoscopy first.


Eligibility criteria:
inclusion criteria: * colonoscopy: screening , surveillance, diagnostic exclusion criteria: * pregnancy * age\<18 years * age \> 80 years * known colonic strictures * chronic inflammatory bowel disease * active inflammation
study to evaluate the efficacy and safety of filgotinib in adults with active noninfectious uveitis

Conditions: Noninfectious Uveitis

Summary: the primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by week 24.


Eligibility criteria:
key inclusion criteria: * is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis * must have active uveitic disease at the day 1/baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral corticosteroid equivalent: * active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion * ≥ 2+ anterior chamber cells per the standardization of uveitis nomenclature (sun) criteria * ≥ 2+ vitreous haze per the national eye institute/standardization of uveitis nomenclature (nei/sun) criteria * no evidence of active tuberculosis (tb) or untreated latent tb key exclusion criteria: * participants with elevated intraocular pressures and/or severe glaucoma * confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to tb, cytomegalovirus (cmv), human t-lymphotropic virus type 1 (htlv-1), whipple's disease, herpes zoster virus (hzv), lyme disease, toxoplasmosis and herpes simplex virus (hsv) note: other protocol defined inclusion/ exclusion criteria may apply.
a study comparing the safety and efficacy of ziprasidone and risperidone for the treatment of chronic schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. the primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal side effects and the secondary purpose is to compare their tolerability and efficacy.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * cgi-s score of 4 or less at baseline exclusion criteria: * concurrent antipsychotic treatment * treatment with antidepressants or mood stabilizers within 2 weeks of randomization * acute exacerbation of schizophrenia within 3 months of baseline